Philip Bonomi to Etoposide
This is a "connection" page, showing publications Philip Bonomi has written about Etoposide.
Connection Strength
0.925
-
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
Score: 0.191
-
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol. 1995 Aug; 22(4 Suppl 9):42-7.
Score: 0.135
-
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
Score: 0.101
-
Recent advances in etoposide therapy for non-small cell lung cancer. Cancer. 1991 Jan 01; 67(1 Suppl):254-9.
Score: 0.098
-
Chemoradiation in locally advanced non-small cell lung cancer. Cancer Treat Res. 2001; 105:171-88.
Score: 0.049
-
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb; 18(3):623-31.
Score: 0.046
-
Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-123-S12-129.
Score: 0.039
-
Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Williston Park). 1997 Apr; 11(4 Suppl 3):9-10.
Score: 0.038
-
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
Score: 0.035
-
Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1994 Jun; 17(3):215-7.
Score: 0.031
-
Platinum/etoposide therapy in non-small cell lung cancer. Oncology. 1992; 49 Suppl 1:43-50.
Score: 0.026
-
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):247-52.
Score: 0.025
-
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4.
Score: 0.020
-
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin Oncol. 1986 Sep; 13(3 Suppl 3):115-20.
Score: 0.018
-
Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide. Cancer Treat Rep. 1985 Sep; 69(9):1007-9.
Score: 0.017
-
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
Score: 0.014
-
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
Score: 0.010
-
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1995 Jul; 13(7):1615-22.
Score: 0.008
-
Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1993 May; 11(5):879-84.
Score: 0.007
-
Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 1990 Dec 01; 66(11):2270-8.
Score: 0.006
-
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
Score: 0.005
-
Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):323-5.
Score: 0.005